These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 31818699)

  • 1. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
    Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
    Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
    Espay AJ; Stocchi F; Pahwa R; Albanese A; Ellenbogen A; Ferreira JJ; Giladi N; Gurevich T; Hassin-Baer S; Hernandez-Vara J; Isaacson SH; Kieburtz K; LeWitt PA; Lopez-Manzanares L; Olanow CW; Poewe W; Sarva H; Yardeni T; Adar L; Salin L; Lopes N; Sasson N; Case R; Rascol O;
    Lancet Neurol; 2024 May; 23(5):465-476. PubMed ID: 38499015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
    Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
    J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
    Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
    Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.
    van der Kolk NM; de Vries NM; Kessels RPC; Joosten H; Zwinderman AH; Post B; Bloem BR
    Lancet Neurol; 2019 Nov; 18(11):998-1008. PubMed ID: 31521532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
    Soileau MJ; Aldred J; Budur K; Fisseha N; Fung VS; Jeong A; Kimber TE; Klos K; Litvan I; O'Neill D; Robieson WZ; Spindler MA; Standaert DG; Talapala S; Vaou EO; Zheng H; Facheris MF; Hauser RA
    Lancet Neurol; 2022 Dec; 21(12):1099-1109. PubMed ID: 36402160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes.
    Isaacson SH; Bowling A; Zhang I; Pappert E; Stocchi F;
    Neurodegener Dis Manag; 2023 Apr; 13(2):75-84. PubMed ID: 36562349
    [No Abstract]   [Full Text] [Related]  

  • 13. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
    Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
    J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
    Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
    Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.
    Thach A; Zichlin ML; Kirson N; Yang K; Gaburo K; Pappert E; Mehta D; Williams GR
    J Comp Eff Res; 2022 Mar; 11(4):285-295. PubMed ID: 35068168
    [No Abstract]   [Full Text] [Related]  

  • 18. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
    Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
    Hauser RA; Cantillon M; Pourcher E; Micheli F; Mok V; Onofrj M; Huyck S; Wolski K
    Lancet Neurol; 2011 Mar; 10(3):221-9. PubMed ID: 21315654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study.
    De Cock VC; Dodet P; Leu-Semenescu S; Aerts C; Castelnovo G; Abril B; Drapier S; Olivet H; Corbillé AG; Leclair-Visonneau L; Sallansonnet-Froment M; Lebouteux M; Anheim M; Ruppert E; Vitello N; Eusebio A; Lambert I; Marques A; Fantini ML; Devos D; Monaca C; Benard-Serre N; Lacombe S; Vidailhet M; Arnulf I; Doulazmi M; Roze E
    Lancet Neurol; 2022 May; 21(5):428-437. PubMed ID: 35429481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.